SCHEMBL246555

SCHEMBL246555

COC(=O)c1ccc(OCc2ccccc2)nc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 6/20 0.60
LMNA P02545 1/20 0.57
HPGD P15428 1/20 0.57
CXCR2 P25025 1/20 0.57
CHRNB2 P17787 1/20 0.57
CHRNA7 P36544 1/20 0.57
CHRNA4 P43681 1/20 0.57
MAPK1 P28482 2/20 0.53
KDM4E B2RXH2 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FFAR1 O14842 1/20 0.50
PABPC1 P11940 1/20 0.50
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7228945 0.92 GABRA5 (0.61) GABRA5LMNACXCR2CHRNB2CHRNA7
SCHEMBL6030328 0.89 GABRA5 (0.53) GABRA5LMNAHPGDCXCR2CHRNB2
SCHEMBL6339006 0.87 OPRM1 (0.57) LMNAMEN1KMT2ASMN1; SMN2PABPC1
SCHEMBL20830743 0.87 CHRNB2 (0.61) LMNAHPGDCXCR2CHRNB2CHRNA7
SCHEMBL1462208 0.86 GABRA5 (0.60) GABRA5LMNAHPGDMAPK1KDM4E
SCHEMBL1255787 0.86 NPC1 (0.55) GABRA5LMNAMAPK1KDM4EL3MBTL1
SCHEMBL1462223 0.86 GABRA5 (0.61) GABRA5LMNACXCR2MAPK1L3MBTL1
SCHEMBL25218277 0.86 LMNA (0.49) GABRA5LMNAHPGDCXCR2CHRNB2
SCHEMBL1463151 0.85 GABRA5 (0.55) GABRA5
SCHEMBL1091737 0.85 MAOB (0.62) LMNACXCR2CHRNB2CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109195608-A Boron-containing small molecules 比尔及梅琳达盖茨基金会 2019-01-11 CN disclosed
EP-2588104-B1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-12-10 EP disclosed
EP-2588104-B1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-12-10 EP disclosed
US-8697690-B2 Isoindolone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-04-15 US disclosed
EP-2588104-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2013-05-08 EP disclosed
US-20130109686-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2013-05-02 US disclosed
US-20130109686-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2013-05-02 US disclosed
US-20130109686-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2013-05-02 US disclosed
EP-2482657-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS Vanderbilt University (US) 2012-08-08 EP disclosed
WO-2012003147-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-01-05 WO disclosed
WO-2012003147-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-01-05 WO disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109686-A1 ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRD1, OPRL1 GABRA5 133/4885LMNA 4267/4885HPGD 980/4885
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 GABRA5 26/4885LMNA 4376/4885HPGD 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.